269 related articles for article (PubMed ID: 35816664)
1. Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for
Mishra A; Tamari R; DeZern AE; Byrne MT; Gooptu M; Chen YB; Deeg HJ; Sallman D; Gallacher P; Wennborg A; Hickman DK; Attar EC; Fernandez HF
J Clin Oncol; 2022 Dec; 40(34):3985-3993. PubMed ID: 35816664
[TBL] [Abstract][Full Text] [Related]
2. Eprenetapopt (APR-246) and Azacitidine in
Sallman DA; DeZern AE; Garcia-Manero G; Steensma DP; Roboz GJ; Sekeres MA; Cluzeau T; Sweet KL; McLemore A; McGraw KL; Puskas J; Zhang L; Yao J; Mo Q; Nardelli L; Al Ali NH; Padron E; Korbel G; Attar EC; Kantarjian HM; Lancet JE; Fenaux P; List AF; Komrokji RS
J Clin Oncol; 2021 May; 39(14):1584-1594. PubMed ID: 33449813
[TBL] [Abstract][Full Text] [Related]
3. Eprenetapopt Plus Azacitidine in
Cluzeau T; Sebert M; Rahmé R; Cuzzubbo S; Lehmann-Che J; Madelaine I; Peterlin P; Bève B; Attalah H; Chermat F; Miekoutima E; Rauzy OB; Recher C; Stamatoullas A; Willems L; Raffoux E; Berthon C; Quesnel B; Loschi M; Carpentier AF; Sallman DA; Komrokji R; Walter-Petrich A; Chevret S; Ades L; Fenaux P
J Clin Oncol; 2021 May; 39(14):1575-1583. PubMed ID: 33600210
[TBL] [Abstract][Full Text] [Related]
4. Eprenetapopt combined with venetoclax and azacitidine in TP53-mutated acute myeloid leukaemia: a phase 1, dose-finding and expansion study.
Garcia-Manero G; Goldberg AD; Winer ES; Altman JK; Fathi AT; Odenike O; Roboz GJ; Sweet K; Miller C; Wennborg A; Hickman DK; Kanagal-Shamanna R; Kantarjian H; Lancet J; Komrokji R; Attar EC; Sallman DA
Lancet Haematol; 2023 Apr; 10(4):e272-e283. PubMed ID: 36990622
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
6. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial.
Platzbecker U; Middeke JM; Sockel K; Herbst R; Wolf D; Baldus CD; Oelschlägel U; Mütherig A; Fransecky L; Noppeney R; Bug G; Götze KS; Krämer A; Bochtler T; Stelljes M; Groth C; Schubert A; Mende M; Stölzel F; Borkmann C; Kubasch AS; von Bonin M; Serve H; Hänel M; Dührsen U; Schetelig J; Röllig C; Kramer M; Ehninger G; Bornhäuser M; Thiede C
Lancet Oncol; 2018 Dec; 19(12):1668-1679. PubMed ID: 30442503
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study.
de Lima M; Giralt S; Thall PF; de Padua Silva L; Jones RB; Komanduri K; Braun TM; Nguyen HQ; Champlin R; Garcia-Manero G
Cancer; 2010 Dec; 116(23):5420-31. PubMed ID: 20672358
[TBL] [Abstract][Full Text] [Related]
8. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis.
Bewersdorf JP; Allen C; Mirza AS; Grimshaw AA; Giri S; Podoltsev NA; Gowda L; Cho C; Tallman MS; Zeidan AM; Stahl M
Transplant Cell Ther; 2021 Dec; 27(12):997.e1-997.e11. PubMed ID: 34551341
[TBL] [Abstract][Full Text] [Related]
9. Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.
Gyurkocza B; Gutman J; Nemecek ER; Bar M; Milano F; Ramakrishnan A; Scott B; Fang M; Wood B; Pagel JM; Baumgart J; Delaney C; Maziarz RT; Sandmaier BM; Estey EH; Appelbaum FR; Storer BE; Deeg HJ
Biol Blood Marrow Transplant; 2014 Apr; 20(4):549-55. PubMed ID: 24440648
[TBL] [Abstract][Full Text] [Related]
10. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.
de Lima M; Oran B; Champlin RE; Papadopoulos EB; Giralt SA; Scott BL; William BM; Hetzer J; Laille E; Hubbell B; Skikne BS; Craddock C
Biol Blood Marrow Transplant; 2018 Oct; 24(10):2017-2024. PubMed ID: 29933073
[TBL] [Abstract][Full Text] [Related]
11. A Phase II Multicenter Study of the Addition of Azacitidine to Reduced-Intensity Conditioning Allogeneic Transplant for High-Risk Myelodysplasia (and Older Patients with Acute Myeloid Leukemia): Results of CALGB 100801 (Alliance).
Vij R; Le-Rademacher J; Laumann K; Hars V; Owzar K; Shore T; Vasu S; Cashen A; Isola L; Shea T; DeMagalhaes-Silverman M; Hurd D; Meehan K; Beardell F; Devine S
Biol Blood Marrow Transplant; 2019 Oct; 25(10):1984-1992. PubMed ID: 31212080
[TBL] [Abstract][Full Text] [Related]
12. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
Bewersdorf JP; Stahl M; Zeidan AM
Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
[TBL] [Abstract][Full Text] [Related]
13. Azacitidine, lenalidomide and donor lymphocyte infusions for relapse of myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia after allogeneic transplant: the Azalena-Trial.
Schroeder T; Stelljes M; Christopeit M; Esseling E; Scheid C; Mikesch JH; Rautenberg C; Jäger P; Cadeddu RP; Drusenheimer N; Holtick U; Klein S; Trenschel R; Haas R; Germing U; Kröger N; Kobbe G
Haematologica; 2023 Nov; 108(11):3001-3010. PubMed ID: 37259567
[TBL] [Abstract][Full Text] [Related]
14. Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.
Sallman DA; Al Malki MM; Asch AS; Wang ES; Jurcic JG; Bradley TJ; Flinn IW; Pollyea DA; Kambhampati S; Tanaka TN; Zeidner JF; Garcia-Manero G; Jeyakumar D; Komrokji R; Lancet J; Kantarjian HM; Gu L; Zhang Y; Tan A; Chao M; O'Hear C; Ramsingh G; Lal I; Vyas P; Daver NG
J Clin Oncol; 2023 May; 41(15):2815-2826. PubMed ID: 36888930
[TBL] [Abstract][Full Text] [Related]
15. Azacitidine Maintenance Therapy Post-Allogeneic Stem Cell Transplantation in Poor-Risk Acute Myeloid Leukemia.
Keruakous AR; Holter-Chakrabarty J; Schmidt SA; Khawandanah MO; Selby G; Yuen C
Hematol Oncol Stem Cell Ther; 2023 Jan; 16(1):52-60. PubMed ID: 36634281
[TBL] [Abstract][Full Text] [Related]
16. Azacitidine for relapse of acute myeloid leukemia or myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation, multicenter PALG analysis.
Drozd-Sokołowska J; Karakulska-Prystupiuk E; Biecek P; Kobylińska K; Piekarska A; Dutka M; Waszczuk-Gajda A; Mądry K; Kopińska A; Gołos A; Góra-Tybor J; Szwedyk P; Bołkun Ł; Czyż A; Giebel S; Basak GW; Dwilewicz-Trojaczek J
Eur J Haematol; 2021 Jul; 107(1):129-136. PubMed ID: 33764578
[TBL] [Abstract][Full Text] [Related]
17. Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome.
Guillaume T; Malard F; Magro L; Labopin M; Tabrizi R; Borel C; Chevallier P; Vigouroux S; Peterlin P; Garnier A; Rubio MT; Huynh A; Milpied N; Moreau P; Gaugler B; Yakoub-Agha I; Mohty M
Bone Marrow Transplant; 2019 Nov; 54(11):1815-1826. PubMed ID: 31089280
[TBL] [Abstract][Full Text] [Related]
18. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
[TBL] [Abstract][Full Text] [Related]
19. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
20. Prophylactic maintenance with venetoclax/azacitidine after reduced-intensity conditioning allogeneic transplant for high-risk MDS and AML.
Garcia JS; Kim HT; Murdock HM; Ansuinelli M; Brock J; Cutler CS; Gooptu M; Ho VT; Koreth J; Nikiforow S; Romee R; Shapiro R; DeAngelo DJ; Stone RM; Bat-Erdene D; Ryan J; Contreras ME; Fell G; Letai A; Ritz J; Lindsley RC; Soiffer RJ; Antin JH
Blood Adv; 2024 Feb; 8(4):978-990. PubMed ID: 38197938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
